-
Intra-Cellular Therapies Inc (NASDAQ: ITCI)
shares tumbled 63.2 percent to $15.60 after its lead product candidate, ITI-007, failed a late-stage study in schizophrenia.
Apparently, the drug couldn't beat the placebo, nor could it equal the performance of the active control risperidone.
-
Alcobra Ltd (NASDAQ: ADHD) shares dipped 55
percent to $2.08 after the company disclosed that the FDA has placed a full clinical hold on its IND applications for MDX in
ADHD and Fragile X Syndrome. The company reported that it has received verbal notice of the clinical hold from the FDA.
-
Marinus Pharmaceuticals Inc (NASDAQ: MRNS)
dropped 28.2 percent to $1.96 after the company reported top-line results from a Phase 2 exploratory open-label clinical trial
evaluating ganaxolone in females with PCDH19 pediatric epilepsy.
-
Shineco Inc (NASDAQ: TYHT) shares fell 27.3
percent to $21.00. On Wednesday, Shineco priced IPO at $4.50 per share.
-
Actinium Pharmaceuticals Inc (NYSE: ATNM) shares
dropped 20.7 percent to $1.34. Actinium priced 8 million shares at $1.25 per share.
-
Real Goods Solar, Inc. (NASDAQ: RGSE) fell 16.3
percent to $4.05. Real Goods Solar shares have dropped 78.96 percent over the past 52 weeks, while the S&P 500 index has
gained 15.25 percent in the same period.
-
Galectin Therapeutics Inc (NASDAQ: GALT) shares
declined 14.2 percent to $1.20. H.C. Wainwright downgraded the rating on Galectin Therapeutics from Buy to Neutral, while
lowering the price target from $8.00 to $1.50.
-
Stein Mart, Inc. (NASDAQ: SMRT) shares dropped 11
percent to $6.71 after the company announced the resignation of Dawn Robertson as CEO. Sidoti & Co. downgraded Stein Mart from
Buy to Neutral.
-
Fitbit Inc (NYSE: FIT) shares declined 9.3 percent
to $15.15. Pacific Crest downgraded Fitbit from Sector Weight to Underweight.
-
Sonus Networks, Inc. (NASDAQ: SONS) fell 9
percent to $7.84. Cowen & Co. downgraded Sonus Networks from Market Perform to Underperform.
-
Kona Grill Inc (NASDAQ: KONA) slipped 8.2 percent
to $12.70. KeyBanc downgraded Kona Grill from Overweight to Sector Weight.
-
Genocea Biosciences Inc (NASDAQ: GNCA) shares
dropped 4.9 percent to $5.44. Genocea Biosciences disclosed that its Phase 2b trial of GEN-003 for genital herpes has achieved
primary endpoint.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.